Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below. Immune-Mediated Pneumonitis IMFINZI can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who ...
Embryo-Fetal Toxicity Based on their mechanism of action and data from animal studies, IMFINZI and IMJUDO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to ini...
With regard to safety management, interstitial lung disease (ILD), including radiation pneumonitis, was most critical in CRT [4,12]. Durvalumab caused a higher frequency of pneumonitis of any grade than the placebo (33.9% and 24.8%, respectively) but not of grade 3 or worse (3.4% and 2.6...
The use of PARP inhibitors and bevacizumab is a routine part of the therapeutic management of AOC, with bevacizumab and olaparib both indicated in relapsed AOC. Current attempts to address the lack of efficacy of immune checkpoints inhibitors in ovarian cancer include a focus on combinatorial strate...
. We acknowledge the generous support of the study sponsors and operations management, QLHC (2013 to present) and the Foundation for the NIH (2010 to 2012; to L.J.E.). We sincerely appreciate the ongoing support for the I-SPY2.2 trial from the Safeway Foundation, the William K. Bowes,...
1. We see some of the infectious work-up that’s now being done, including [coronavirus disease 2019] swabs….For grade 1 toxicity, it’s sometimes hard to tell if it’s just radiation change or if it’s checkpoint inhibition. Typically, we try to have repeat chest imaging in a...
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials ESMO Open, 6 (2021), p. 100124 View PDFView articleView in ScopusGoogl...
7Place of Durvalumab in the Management of Extensive-Stage SCLC Recommendations for the use of durvalumab in combination with etoposide and either carboplatin or cisplatin are included in the NCCN [17] and ESMO [18] clinical practice guidelines for SCLC. In the USA, the preferred regimens to be...
. We acknowledge the generous support of the study sponsors and operations management, QLHC (2013 to present) and the Foundation for the NIH (2010 to 2012; to L.J.E.). We sincerely appreciate the ongoing support for the I-SPY2.2 trial from the Safeway Foundation, the William K. Bowes,...
DLT was defined as any grade 4 immune-related adverse event (irAE), any grade 3 irAE that did not resolve to grade 2 within 3 days despite optimal management or did not resolve to ≤grade 1 within 14 days, and any ≥grade 3 non-irAE causally attributed to durvalumab. The primary ...